{"analyses":[{"ciLowerLimit":"3.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"20.2","estimateComment":"The Kaplan Meier method was used to estimate median time to next treatment (in months). The Greenwood method was used to estimate confidence limits of median time to next treatment.","groupIds":["OG000"],"nonInferiorityComment":"Estimation only","nonInferiorityType":"OTHER","paramType":"Median","paramValue":"12.1"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"20.2","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"TTNT will be calculated from the time of treatment start until the start of the first subsequent anti-cancer therapy after all protocol directed therapy is completed. For surviving subjects who do not receiving subsequent therapy, TTNT will be censored at the last contact date. For subjects who die before beginning subsequent anti-cancer therapy, TTNT will be censored at the date of death","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (4 28-day cycles):\n\nCarfilzomib (IV) @ 20 mg/m\\^2, Day 1 of Cycle 1; @ 56 mg/m\\^2, Day 8,15 of Cycle 1; @ 56 mg/m\\^2, Day 1,8,15 of Cycles 2-4\n\nLenalidomide (Oral) @ 25 mg, once daily at bedtime on Days 1-21 of each cycle (Cycles 1-4)\n\nDexamethasone @ 28 mg orally OR 8 mg IV, once weekly on Day 1,8,15,22 of Cycles 1-2; @28 mg orally OR 8 mg IV on Day 1 of Cycles 3-4\n\nElotuzumab (IV) @ 10 mg/kg, once weekly on Day 1,8,15,22 of Cycles 1-2; @ 20 mg/kg on Day 1 of Cycles 3-4\n\nMaintenance (28-day cycles):\n\nElotuzumab (IV) @ 20 mg/kg, Day 1 of each cycle (Cycles 1-n)\n\nLenalidomide (Oral) @ 15 mg (or last tolerated dose if \\<15 mg), once daily at bedtime on Days 1-21 of each cycle (Cycles 1-n)","id":"OG000","title":"KRd-Elotuzumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all subjects who initiated Elo-KRd.","reportingStatus":"POSTED","timeFrame":"From treatment start date to date of next treatment, or censored as described; assessed for approximately 3 years.","title":"Time to Next Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"months"}